Caroline Cole Block, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Inflammatory Breast Neoplasms | 2 | 2021 | 143 | 0.340 |
Why?
|
Breast Neoplasms | 10 | 2023 | 20822 | 0.230 |
Why?
|
Acupuncture, Ear | 1 | 2022 | 13 | 0.210 |
Why?
|
Filgrastim | 1 | 2020 | 133 | 0.180 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2020 | 332 | 0.140 |
Why?
|
Paclitaxel | 2 | 2021 | 1708 | 0.140 |
Why?
|
Interdisciplinary Communication | 1 | 2021 | 950 | 0.130 |
Why?
|
Polyethylene Glycols | 1 | 2020 | 1182 | 0.120 |
Why?
|
Cyclophosphamide | 1 | 2020 | 2242 | 0.120 |
Why?
|
Doxorubicin | 1 | 2020 | 2234 | 0.110 |
Why?
|
Aromatase Inhibitors | 1 | 2014 | 491 | 0.090 |
Why?
|
Premenopause | 1 | 2014 | 1033 | 0.090 |
Why?
|
Medical Oncology | 2 | 2021 | 2265 | 0.090 |
Why?
|
Tamoxifen | 1 | 2014 | 981 | 0.090 |
Why?
|
Nitriles | 1 | 2014 | 956 | 0.080 |
Why?
|
Triazoles | 1 | 2014 | 911 | 0.080 |
Why?
|
Thyroid Neoplasms | 1 | 2020 | 2282 | 0.070 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11524 | 0.070 |
Why?
|
Spinal Cord Compression | 2 | 1999 | 235 | 0.070 |
Why?
|
Benzimidazoles | 1 | 2011 | 850 | 0.070 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2014 | 1524 | 0.070 |
Why?
|
Mammography | 1 | 2012 | 2476 | 0.050 |
Why?
|
Phthalazines | 1 | 2023 | 363 | 0.050 |
Why?
|
Premedication | 1 | 2021 | 258 | 0.050 |
Why?
|
Pyridines | 1 | 2011 | 2825 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2023 | 9239 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2020 | 220 | 0.040 |
Why?
|
Nausea | 1 | 2022 | 673 | 0.040 |
Why?
|
Venous Thromboembolism | 1 | 2011 | 1671 | 0.040 |
Why?
|
Vomiting | 1 | 2022 | 636 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2022 | 5078 | 0.040 |
Why?
|
Early Detection of Cancer | 1 | 2012 | 3086 | 0.040 |
Why?
|
BRCA2 Protein | 1 | 2023 | 794 | 0.040 |
Why?
|
Practice Guidelines as Topic | 2 | 2012 | 7279 | 0.040 |
Why?
|
Female | 16 | 2023 | 380194 | 0.040 |
Why?
|
Models, Statistical | 1 | 2012 | 5102 | 0.040 |
Why?
|
BRCA1 Protein | 1 | 2023 | 1149 | 0.040 |
Why?
|
Risk Assessment | 4 | 2012 | 23338 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1788 | 0.030 |
Why?
|
Thyroidectomy | 1 | 2020 | 879 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2023 | 2187 | 0.030 |
Why?
|
Bone Marrow Transplantation | 2 | 1992 | 2765 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2021 | 2924 | 0.030 |
Why?
|
American Cancer Society | 1 | 2012 | 61 | 0.030 |
Why?
|
Pedigree | 1 | 2020 | 4644 | 0.030 |
Why?
|
Humans | 17 | 2023 | 744343 | 0.030 |
Why?
|
Antithrombin Proteins | 1 | 2011 | 9 | 0.030 |
Why?
|
Ovarian Neoplasms | 1 | 2009 | 4838 | 0.030 |
Why?
|
Spinal Neoplasms | 1 | 1999 | 760 | 0.030 |
Why?
|
Ovariectomy | 1 | 2014 | 661 | 0.030 |
Why?
|
Leukopenia | 1 | 1992 | 212 | 0.020 |
Why?
|
Economics, Pharmaceutical | 1 | 2011 | 87 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2021 | 2416 | 0.020 |
Why?
|
Survival Analysis | 2 | 2021 | 10252 | 0.020 |
Why?
|
Anemia, Hemolytic | 1 | 1992 | 168 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2021 | 4851 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6756 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8642 | 0.020 |
Why?
|
Middle Aged | 8 | 2021 | 213383 | 0.020 |
Why?
|
Spinal Cord Diseases | 1 | 1992 | 298 | 0.020 |
Why?
|
Risk Management | 1 | 2012 | 571 | 0.020 |
Why?
|
Aged | 6 | 2023 | 163280 | 0.020 |
Why?
|
Retrospective Studies | 5 | 2023 | 77449 | 0.020 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2014 | 1205 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2021 | 12245 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12354 | 0.020 |
Why?
|
Needs Assessment | 1 | 2012 | 1147 | 0.020 |
Why?
|
Prospective Studies | 2 | 2021 | 53288 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2014 | 3479 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2012 | 35421 | 0.020 |
Why?
|
Medical History Taking | 1 | 2009 | 783 | 0.020 |
Why?
|
Survival Rate | 2 | 2014 | 12788 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 1992 | 1179 | 0.010 |
Why?
|
Adult | 7 | 2020 | 214055 | 0.010 |
Why?
|
Body Mass Index | 1 | 2020 | 12720 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2020 | 21746 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2012 | 2266 | 0.010 |
Why?
|
Phylogeny | 1 | 2009 | 2803 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8388 | 0.010 |
Why?
|
Patient Selection | 1 | 2012 | 4215 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2014 | 11031 | 0.010 |
Why?
|
United States | 2 | 2021 | 69872 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 2 | 2012 | 17446 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2021 | 57776 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2009 | 2278 | 0.010 |
Why?
|
Risk Factors | 3 | 2020 | 72290 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2011 | 5391 | 0.010 |
Why?
|
Child, Preschool | 1 | 2020 | 41006 | 0.010 |
Why?
|
Prognosis | 2 | 2014 | 29063 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2014 | 39050 | 0.010 |
Why?
|
Genetic Testing | 1 | 2009 | 3444 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2009 | 3229 | 0.010 |
Why?
|
Cohort Studies | 2 | 2012 | 40561 | 0.010 |
Why?
|
Young Adult | 1 | 2020 | 56430 | 0.010 |
Why?
|
Logistic Models | 2 | 1999 | 13408 | 0.010 |
Why?
|
Mass Screening | 1 | 2009 | 5255 | 0.010 |
Why?
|
Medical Records | 1 | 1998 | 1413 | 0.010 |
Why?
|
Child | 1 | 2020 | 77709 | 0.010 |
Why?
|
Blotting, Southern | 1 | 1992 | 803 | 0.010 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1992 | 768 | 0.010 |
Why?
|
Neurology | 1 | 1999 | 763 | 0.010 |
Why?
|
Splenectomy | 1 | 1992 | 395 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 1998 | 12959 | 0.010 |
Why?
|
Quality of Life | 1 | 2011 | 12804 | 0.010 |
Why?
|
Forecasting | 1 | 1999 | 2951 | 0.010 |
Why?
|
Pain Measurement | 1 | 1998 | 3420 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 1992 | 2505 | 0.000 |
Why?
|
Immunoglobulins, Intravenous | 1 | 1992 | 652 | 0.000 |
Why?
|
Patient Care Team | 1 | 1999 | 2531 | 0.000 |
Why?
|
Prednisone | 1 | 1992 | 1574 | 0.000 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1992 | 689 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 2 | 1999 | 20129 | 0.000 |
Why?
|
Radiology | 1 | 1999 | 2100 | 0.000 |
Why?
|
Palliative Care | 1 | 1999 | 3493 | 0.000 |
Why?
|
Chromosome Mapping | 1 | 1992 | 4740 | 0.000 |
Why?
|
Male | 4 | 2009 | 350118 | 0.000 |
Why?
|
Flow Cytometry | 1 | 1992 | 5974 | 0.000 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 1992 | 3523 | 0.000 |
Why?
|
Adolescent | 1 | 1999 | 85781 | 0.000 |
Why?
|